about
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanomaSequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.Utility of adjuvant systemic therapy in melanoma.Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialReport from the Melanoma Independent Board First Melanoma MIB Conference, 21-22 October 2013.Pediatric melanoma: analysis of an international registryDiagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in ItalyReport from the second MIB (Melanoma Independent Board) Conference, 27-28 October 2014The risk of developing a second primary cancer in melanoma patients: a comprehensive review of the literature and meta-analysis.Combined approach for the biomechanical characterization of skin lesions.Tuning of a deformable image registration procedure for skin component mechanical properties assessment.Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensiDiagnosis of melanoma in the elderly and surgical implications.Heat shock proteins and their use as anticancer vaccines.In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.Update: current management issues in malignant melanoma.Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases.Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.Surgery and radiotherapy in the treatment of cutaneous melanomaProspective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeThe immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.Treatment of metastatic melanoma with electrochemotherapy.Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline.A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma.Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma.Diagnosis and treatment of in-transit melanoma metastases.Unknown Primary Melanoma: Worldwide Survey on Clinical Management.
P50
Q28235082-63815102-A0A4-4F60-A7F0-28A0A76593C2Q30746423-B22088FF-C856-4001-B08B-A7ECE7ABE1CBQ33396664-4664CE99-085D-4310-9561-63DA2C8FF591Q33413244-3F238540-F11D-42E8-8CF0-9F1C6DBE83FBQ33484065-ABECAA00-0EBF-406A-9396-0A053109EF0CQ33643902-2E9F1CC5-E2A0-4EE9-8BCB-F70804AF2A73Q33749057-4DE2DAB6-EF2C-4D99-8F36-2B24893BEC33Q33893940-C9FA5CFA-30E8-4D20-9149-C484EA9732E6Q33894797-B62B7B31-06F1-4282-B35C-CCAD0281DB68Q34487294-AD008D4B-85D3-497A-B8F6-42D72F677BB0Q34515007-5982D273-8385-460A-AA51-52B792637851Q34656538-5EB788CA-D931-4FF4-B4BF-D5156F1C0C88Q34671756-391B1E88-95C8-498D-B6B1-1F6500D54347Q35041046-98BC64F4-090C-4969-BA04-8E3D0D6181C4Q35106178-5586661E-E025-4E38-9B6E-AACF2F58AF65Q35134630-B01C6592-A6A0-4839-946C-964523F99266Q35886967-E690B66E-C802-4A3D-845C-4AC5557234EAQ35887145-F1F58291-0FE5-47D6-AF96-EF5BC4B546AEQ35899104-D446322D-9367-4DC7-A6C9-E3817061D8AFQ35992187-B8B3A3B4-8281-4CC9-9A78-046971362E47Q35995757-735C697E-899D-4087-8A82-78AD96657C7CQ36017883-DDBB957C-685C-4C8F-AA8E-E8C2BBEBDCF7Q36265494-513C438C-9650-4EC3-85D1-4F4C887214B1Q36893988-81F9A7AE-D15D-49DE-A919-B8B18AF61AF5Q37185333-479468BE-CDB0-4FB9-A7D2-086CB50F4A2FQ37266677-4633C1B9-A5B2-43FC-8061-4351A8CF21E6Q37281267-9DC8AC70-679F-4D83-9826-70E750543480Q37417271-6C089B91-06E7-421B-B95D-67AC2683BA77Q37681718-B686481B-0DF9-4C02-A7DE-A422BBB9253BQ37718203-AAA861D3-8164-4A27-9B78-F740E175116EQ37908142-0DDAE201-F849-405F-A6C6-D3569DBB7FA9Q38199545-D621865C-5CCE-4C0B-B44F-382A83BAE5FCQ38200101-07070648-7248-42A5-AF12-B8853DAF7043Q38563536-0765AD6A-43A3-4A8C-8F9C-C119EB1FDD08Q38593792-AA86A525-2C70-4846-95BC-FFBF3E429F59Q38738044-9DA0E991-5B7F-4233-A26E-8845EEA2FDE9Q38948856-80A9F85E-C18D-4EBD-8FB2-1F3CEB4504ADQ38951984-75F33374-E81B-4FFE-A633-BC7936E89F31Q39030916-C0B7F1D5-F1B6-49C4-BC8E-397B92BC9529Q39067154-24429239-0B81-40FC-BF9D-A2E67F18634D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Alessandro Testori
@en
Alessandro Testori
@nl
type
label
Alessandro Testori
@en
Alessandro Testori
@nl
prefLabel
Alessandro Testori
@en
Alessandro Testori
@nl
P31
P496
0000-0003-3685-0210